Loading, Please Wait...
OTTAWA, ONTARIO--(Marketwired - Mar 24, 2016) - Patented Medicine Prices Review Board
The Patented Medicine Prices Review Board (PMPRB) will hold a public hearing with respect to allegations that Baxalta Canada Corporation failed to provide the PMPRB with the pricing and sales information required by section 80 of the Patent Act and sections 3 and 4 of the Patented Medicine Regulations. The proceeding relates to the medicine Oncaspar, which is sold in Canada under Health Canada's Special Access Programme and is used in the treatment of patients with Acute Lymphoblastic Leukemia.
The purpose of the hearing is to receive evidence and argument of Board Staff, Baxalta Canada Corporation, and any interveners regarding allegations that Baxalta Canada Corporation is in breach of its reporting requirements. The date, time, and location of the public hearing will be set and confirmed at a later date.
Those wishing to participate in this proceeding must apply to the Board for leave to intervene by May 2, 2016. For more information on the application process, please contact:
|Director, Board Secretariat|
|Patented Medicine Prices Review Board|
|Box L40, 333 Laurier Avenue West, Suite 1400|
|Ottawa, Ontario K1P 1C1|
Patented Medicine Prices Review Board